PUF Ventures and Cannvas Medtech announced today that they have completed a statutory arrangement under a plan of arrangement and as a result MTEC became a reporting issuer in the provinces of British Columbia, Alberta and Ontario.
Nuvo Pharmaceuticals (TSX:NRI; OTCQX:NRIFF) announced its Ireline subsidiary acquired the U.S. rights of Resultz from Piedmont Pharmaceuticals.
As quoted in the press release:
The acquisition includes all U.S. product and intellectual property rights and is a complementary follow-on to Nuvo’s acquisition of the global, ex-U.S. Resultz product rights announced on January 2, 2018. Nuvo now owns
In case you missed it, here is this week’s big news roundup in the Life Science sector.
INN brings the latest from the last day of the Biotech Showcase conference in San Francisco.
By Jocelyn Aspa
Bradmer Pharmaceuticals (NEX:BMR.H) has announced that it has entered into a letter of intent dated January 9, 2018 with Galaxy Digital LP and First Coin Capital to form a new enterprise in the blockchain, digital asset and cryptocurrency space.
As quoted in the press release:
The series of transactions contemplated by the
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has partnered with Mr. Charles (Chuck) Austin and JK Advisors in order to scale up operational
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Peregrine Pharmaceuticals announced a change in its name and ticker symbol, respectively to Avid Bioservices and CDMO, as part of its transition as a contract development and manufacturing organization.
By Pia Rivera
Phivida Holdings Inc. (CSE:VIDA) is pleased to announce the launch of its flagship line of high performance Nano-CBD™ (nanoencapsulated-cannabidiol) infused beverages into the US athletic and sports medicine market.
Phivida Nano-CBD™ Sport line of beverages are designed to maximize physical, mental performance for athletes, fitness professionals and everyday health conscious consumers.
The Investing News Network takes a look at the major developments from the world of biotech in 2017.
Inovio Pharmaceuticals announced an agreement to provide ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100, an immunotherapy product designed to treat pre-cancers caused by HPV, within Greater China.
Nuvo Pharmaceuticals announced it acquired the global rights for Resultz, a treatment for head lice from Piedmont Pharmaceuticals.
Cannabis is on a path of expansion, from the US market expanding to the expected legalization of recreational cannabis in Canada. INN takes a closer look at the challenges and possibilities approaching in 2018.
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate, VAL-083, in recurrent glioblastoma (rGBM).